share_log

LadRx (NASDAQ:CYTR) Now Covered by StockNews.com

LadRx (NASDAQ:CYTR) Now Covered by StockNews.com

LadrX(納斯達克股票代碼:CYTR)現已由 StockNews.com 報道
Defense World ·  2023/03/29 13:34

Stock analysts at StockNews.com assumed coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report released on Wednesday. The firm set a "hold" rating on the stock.

StockNews.com的股票分析師假設對以下股票進行了報道 LadRx(納斯達克股票代碼:CYTR — 獲取評級) 在週三發佈的一份報告中。該公司對該股設定了 “持有” 評級。

LadRx Stock Performance

LadrX 股票表現

LadRx has a 52-week low of $0.05 and a 52-week high of $0.86. The firm's 50 day moving average price is $0.10.

LadRx創下52周低點0.05美元,52周高點爲0.86美元。該公司的50天移動平均價格爲0.10美元。

Get
獲取
LadRx
LadRx
alerts:
警報:

LadRx Company Profile

LadrX 公司簡介

(Get Rating)

(獲取評級)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.

LadRx Corp. 是一家生物製藥研發公司,從事新型抗癌候選藥物的發現、研究和臨床開發。它專注於開發Linker Activated Drue Release(LADR)技術平臺,該平臺是一個發現引擎,可幫助創建抗癌分子管道,避免不可接受的全身毒性,同時將高效藥物直接輸送到腫瘤。

Featured Articles

精選文章

  • Get a free copy of the StockNews.com research report on LadRx (CYTR)
  • After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
  • Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
  • Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
  • The Bottom Is In For McCormick & Company
  • Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
  • 免費獲取 StockNews.com 關於 LadrX (CYTR) 的研究報告
  • 在收益井噴之後,Ciena 股票是買入機會嗎?
  • Meta 突破了基礎,看起來又像成長型股票了
  • 這就是爲甚麼Viking Therapeutics根據肥胖藥物數據上漲了50%以上的原因
  • McCormick & Company 已經觸底了
  • Walgreens Boots Alliance:藍籌股、高收益轉型故事

Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.

每天接收 LadRx 的新聞和評級 -在下面輸入您的電子郵件地址,即可通過Marketbeat.com的免費每日電子郵件時事通訊接收LadrX及相關公司的最新新聞和分析師評級的簡明每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論